Effectiveness, cost-utility and implementation of a decision aid for patients with localised prostate cancer and their partners: Study protocol of a stepped-wedge cluster randomised controlled trial

Hoda H.M. Al-Itejawi, Cornelia F. Van Uden-Kraan, Peter M. Van De Ven, Veerle M.H. Coupé, André N. Vis, Jakko A. Nieuwenhuijzen, Jeroen A. Van Moorselaar, Irma M. Verdonck-De Leeuw*

*Corresponding author for this work

Research output: Contribution to JournalArticleAcademicpeer-review


Introduction Patient decision aids (PDAs) have been developed to help patients make an informed choice for a treatment option. Despite proven benefits, structural implementation falls short of expectations. The present study aims to assess the effectiveness and cost-utility of the PDA among newly diagnosed patients with localised prostate cancer and their partners, alongside implementation of the PDA in routine care. Methods/analysis A stepped-wedge cluster randomised trial will be conducted. The PDA will be sequentially implemented in 18 hospitals in the Netherlands, over a period of 24 months. Every 3 or 6 months, a new cluster of hospitals will switch from usual care to care including a PDA. The primary outcome measure is decisional conflict experienced by the patient. Secondary outcomes comprise the patient's quality of life, treatment preferences, role in the decision making, expectations of treatment, knowledge, need for supportive care and decision regret. Furthermore, societal cost-utility will be valued. Other outcome measures considered are the partner's treatment preferences, experienced participation to decision making, quality of life, communication between patient, partner and health care professional, and the effect of prostate cancer on the relationship, social contacts and their role as caregiver. Patients and partners receiving the PDA will also be asked about their satisfaction with the PDA. Baseline assessment takes place after the treatment choice and before the start of a treatment, with follow-up assessments at 3, 6 and 12 months following the end of treatment or the day after deciding on active surveillance. Outcome measures on implementation include the implementation rate (defined as the proportion of all eligible patients who will receive a PDA) and a questionnaire for health care professionals on determinants of implementing an innovation. Ethics and dissemination This study will be conducted in accordance with local laws and regulations of the Medical Ethics Committee of VU University Medical Center, Amsterdam, The Netherlands. The results from this stepped-wedge trial will be presented at scientific meetings and published in peer-reviewed journals. Trial registration Nederlands Trial Register NTR TC5177, registration date: May 28 th 2015.Pre-results.

Original languageEnglish
Article numbere015154
JournalBMJ Open
Issue number9
Publication statusPublished - 1 Sept 2017


of DAs for prostate cancer in three regions in the Netherlands (the JIPPA study), co-initiated and funded by CZ, a not-for-profit Health Insurance Company. We thank dr. Linda van Mierlo from CZ for her efforts in bringing the three research groups together and for the useful input and critical feedback we received during the progress of this project. In addition, we would like to thank Astellas Pharmaceuticals for the co-funding of this project. Funding This research project is funded by the CZ Innovation Fund (grant 2013–00070) and co-funded by an unrestricted educational grant from Astellas Pharmaceuticals (grant PAS-596). These funding sources had no involvement in data collection, analysis, the preparation of this manuscript or the decision to submit the article for publication.

FundersFunder number
Astellas PharmaceuticalsPAS-596
CZ Innovation Fund2013–00070
Health Insurance Company


    • decision aid
    • prostate cancer
    • protocol
    • Shared decision making


    Dive into the research topics of 'Effectiveness, cost-utility and implementation of a decision aid for patients with localised prostate cancer and their partners: Study protocol of a stepped-wedge cluster randomised controlled trial'. Together they form a unique fingerprint.

    Cite this